Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome.
Hargarten JC, Ssebambulidde K, Anjum SH, Vaughan MJ, Xu J, Ganguly A, Dulek B, Otaizo-Carrasquero F, Song B, Tao S, Park YD, Scott TL, Höltermann TA, Schinazi RF, Chittiboina P, Billioux BJ, Hammoud DA, Olszewski MA, Williamson PR.
Hargarten JC, et al.
Sci Adv. 2025 Mar 21;11(12):eadi9885. doi: 10.1126/sciadv.adi9885. Epub 2025 Mar 21.
Sci Adv. 2025.
PMID: 40117367
Free PMC article.